Welcome to our dedicated page for Newbury Street Acquisition SEC filings (Ticker: NBSTU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trust-account math, warrant re-measurements, and redemption deadlines make Newbury Street Acquisition Corporation Units (NBSTU) filings a challenge for even seasoned SPAC followers. If you have ever searched "Newbury Street Acquisition Corporation Units SEC filings explained simply" or wondered where the next 8-K will surface details of a proposed business combination, you know how quickly the paperwork stacks up.
Stock Titan’s AI pares those documents down to what matters. Open a "Newbury Street Acquisition Corporation Units quarterly earnings report 10-Q filing" and our summaries pinpoint trust account balances and outstanding public warrants in seconds. Need the latest "Newbury Street Acquisition Corporation Units insider trading Form 4 transactions"? Real-time alerts flag every sponsor purchase or sale, while side-by-side tables clarify dilution scenarios. You can also dive into the "Newbury Street Acquisition Corporation Units proxy statement executive compensation" to see how the promote aligns interests, or scan an "8-K material events explained" breakdown when merger terms drop at midnight.
Because NBSTU is still hunting for a target, each disclosure can signal timeline shifts. Use our platform to:
- Track "Newbury Street Acquisition Corporation Units Form 4 insider transactions real-time" before redemption windows close
- Read a "Newbury Street Acquisition Corporation Units annual report 10-K simplified" for covenant details
- Access "Newbury Street Acquisition Corporation Units earnings report filing analysis" to compare trust yields quarter-over-quarter
The Schedule 13G filed on 3 July 2025 reveals that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC collectively own 153,219 Bone Biologics Corporation (BBLG) common shares, equal to 9.99 % of the class. The position consists of 148,500 issued shares and 4,791 shares underlying Intracoastal Warrant 2; all voting and dispositive power is shared among the three reporting persons.
The stake originates from a Securities Purchase Agreement signed on 27 June 2025, under which the Company issued 60,000 shares and seven separate warrants to Intracoastal. Each warrant carries an ownership “blocker” that prevents exercise if the group’s beneficial ownership would exceed 9.99 % (or 4.99 % for several smaller warrants). Because of these blockers the group remains below the 10 % threshold required for Section 16 reporting.
Without the blocker provisions, the reporting group could control up to 821,294 shares immediately after the SPA and 719,794 shares as of 3 July 2025—more than 1.3× the 545,260 shares outstanding on 20 June 2025—indicating significant potential dilution for existing holders if the warrants become exercisable.
The certification section states the securities were not acquired to influence control of the issuer. Nonetheless, investors should monitor (1) the pace of warrant exercises, (2) any amendments to blocker thresholds, and (3) future Schedule 13D/G updates that could signal a change in intent or ownership.
The Schedule 13G filed on 3 July 2025 reveals that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC collectively own 153,219 Bone Biologics Corporation (BBLG) common shares, equal to 9.99 % of the class. The position consists of 148,500 issued shares and 4,791 shares underlying Intracoastal Warrant 2; all voting and dispositive power is shared among the three reporting persons.
The stake originates from a Securities Purchase Agreement signed on 27 June 2025, under which the Company issued 60,000 shares and seven separate warrants to Intracoastal. Each warrant carries an ownership “blocker” that prevents exercise if the group’s beneficial ownership would exceed 9.99 % (or 4.99 % for several smaller warrants). Because of these blockers the group remains below the 10 % threshold required for Section 16 reporting.
Without the blocker provisions, the reporting group could control up to 821,294 shares immediately after the SPA and 719,794 shares as of 3 July 2025—more than 1.3× the 545,260 shares outstanding on 20 June 2025—indicating significant potential dilution for existing holders if the warrants become exercisable.
The certification section states the securities were not acquired to influence control of the issuer. Nonetheless, investors should monitor (1) the pace of warrant exercises, (2) any amendments to blocker thresholds, and (3) future Schedule 13D/G updates that could signal a change in intent or ownership.
FAQ
What is the current stock price of Newbury Street Acquisition (NBSTU)?
What is Newbury Street Acquisition Corporation Units (NBSTU)?
In which industries does NBSTU focus its acquisitions?
What is the current focus of NBSTU?
What sets NBSTU apart in the SPAC landscape?
What is the financial condition of NBSTU?
